Isabella Gomes1, Daniel Antunes Moreno1, Mariana Bisarro Dos Reis1, Luciane Sussuchi da Silva1, Letícia Ferro Leal1,2, Gisele Melo Gonçalves3, Caio Augusto Pereira3, Marco Antônio Oliveira4, Marcus de Medeiros Matsushita5, Rui Manuel Reis6,7,8. 1. Molecular Oncology Research Center, Barretos Cancer Hospital (BCH), Rua Antenor Duarte Villela, 1331, Barretos, SP, CEP 14784 400, Brazil. 2. Barretos School of Health Sciences, Dr. Paulo Prata - FACISB, Barretos, Brazil. 3. Department of Medical Oncology, BCH, Barretos, SP, Brazil. 4. Nucleus of Epidemiology and Statistics, BCH, Barretos, SP, Brazil. 5. Pathology Department, BCH, Barretos, SP, Brazil. 6. Molecular Oncology Research Center, Barretos Cancer Hospital (BCH), Rua Antenor Duarte Villela, 1331, Barretos, SP, CEP 14784 400, Brazil. ruireis.hcb@gmail.com. 7. ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal. ruireis.hcb@gmail.com. 8. Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal. ruireis.hcb@gmail.com.
Abstract
INTRODUCTION: Glioblastoma (GBM) is the deadliest primary brain tumor. The standard treatment consists of surgery, radiotherapy, and temozolomide (TMZ). TMZ response is heterogeneous, and MGMT promoter (MGMTp) methylation has been the major predictive biomarker. We aimed to describe the clinical and molecular data of GBMs treated with TMZ, compare MGMT methylation with MGMT expression, and further associate with patient's outcome. METHODS: We evaluate 112 FFPE adult GBM cases. IDH1 and ATRX expression was analyzed by immunohistochemistry, hotspot TERT promoter (TERTp) mutations were evaluated by Sanger or pyrosequencing, and MGMTp methylation was assessed by pyrosequencing and MGMT mRNA expression using the nCounter® Vantage 3D™ DNA damage and repair panel. RESULTS: Of the 112 GBMs, 96 were IDH1WT, and 16 were IDH1MUT. Positive ATRX expression was found in 91.6% (88/96) of IDHWT and 43.7% (7/16) of IDHMUT. TERTp mutations were detected in 70.4% (50/71) of IDHWT. MGMTp methylation was found in 55.5% (35/63) of IDHWT and 84.6% (11/13) of IDHMUT, and as expected, MGMTp methylation was significantly associated with a better response to TMZ. MGMT expression was inversely correlated with MGMTp methylation levels (- 0.506, p < 0.0001), and MGMT low expression were significantly associated with better patient survival. It was also observed that integrating MGMTp methylation and expression, significantly improved the prognostication value. CONCLUSIONS: MGMT mRNA levels evaluated by digital expression were associated with the outcome of TMZ-treated GBM patients. The combination of MGMT methylation and mRNA expression may provide a more accurate prediction of TMZ response in GBM patients.
INTRODUCTION:Glioblastoma (GBM) is the deadliest primary brain tumor. The standard treatment consists of surgery, radiotherapy, and temozolomide (TMZ). TMZ response is heterogeneous, and MGMT promoter (MGMTp) methylation has been the major predictive biomarker. We aimed to describe the clinical and molecular data of GBMs treated with TMZ, compare MGMT methylation with MGMT expression, and further associate with patient's outcome. METHODS: We evaluate 112 FFPE adult GBM cases. IDH1 and ATRX expression was analyzed by immunohistochemistry, hotspot TERT promoter (TERTp) mutations were evaluated by Sanger or pyrosequencing, and MGMTp methylation was assessed by pyrosequencing and MGMT mRNA expression using the nCounter® Vantage 3D™ DNA damage and repair panel. RESULTS: Of the 112 GBMs, 96 were IDH1WT, and 16 were IDH1MUT. Positive ATRX expression was found in 91.6% (88/96) of IDHWT and 43.7% (7/16) of IDHMUT. TERTp mutations were detected in 70.4% (50/71) of IDHWT. MGMTp methylation was found in 55.5% (35/63) of IDHWT and 84.6% (11/13) of IDHMUT, and as expected, MGMTp methylation was significantly associated with a better response to TMZ. MGMT expression was inversely correlated with MGMTp methylation levels (- 0.506, p < 0.0001), and MGMT low expression were significantly associated with better patient survival. It was also observed that integrating MGMTp methylation and expression, significantly improved the prognostication value. CONCLUSIONS:MGMT mRNA levels evaluated by digital expression were associated with the outcome of TMZ-treated GBM patients. The combination of MGMT methylation and mRNA expression may provide a more accurate prediction of TMZ response in GBM patients.
Authors: Michael Weller; Martin van den Bent; Jörg C Tonn; Roger Stupp; Matthias Preusser; Elizabeth Cohen-Jonathan-Moyal; Roger Henriksson; Emilie Le Rhun; Carmen Balana; Olivier Chinot; Martin Bendszus; Jaap C Reijneveld; Frederick Dhermain; Pim French; Christine Marosi; Colin Watts; Ingela Oberg; Geoffrey Pilkington; Brigitta G Baumert; Martin J B Taphoorn; Monika Hegi; Manfred Westphal; Guido Reifenberger; Riccardo Soffietti; Wolfgang Wick Journal: Lancet Oncol Date: 2017-05-05 Impact factor: 41.316
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: M Esteller; J Garcia-Foncillas; E Andion; S N Goodman; O F Hidalgo; V Vanaclocha; S B Baylin; J G Herman Journal: N Engl J Med Date: 2000-11-09 Impact factor: 91.245
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Bill H Diplas; Xujun He; Jacqueline A Brosnan-Cashman; Heng Liu; Lee H Chen; Zhaohui Wang; Casey J Moure; Patrick J Killela; Daniel B Loriaux; Eric S Lipp; Paula K Greer; Rui Yang; Anthony J Rizzo; Fausto J Rodriguez; Allan H Friedman; Henry S Friedman; Sizhen Wang; Yiping He; Roger E McLendon; Darell D Bigner; Yuchen Jiao; Matthew S Waitkus; Alan K Meeker; Hai Yan Journal: Nat Commun Date: 2018-05-25 Impact factor: 14.919
Authors: Paul Daniel; Siham Sabri; Ahmad Chaddad; Brian Meehan; Bertrand Jean-Claude; Janusz Rak; Bassam S Abdulkarim Journal: Front Oncol Date: 2019-02-04 Impact factor: 6.244
Authors: Diocésio Alves Pinto de Andrade; Luciane Sussuchi da Silva; Ana Carolina Laus; Marcos Alves de Lima; Gustavo Nóriz Berardinelli; Vinicius Duval da Silva; Graziela de Macedo Matsushita; Murilo Bonatelli; Aline Larissa Virginio da Silva; Adriane Feijó Evangelista; Jesus Paula Carvalho; Rui Manuel Reis; Ricardo Dos Reis Journal: Front Oncol Date: 2021-08-17 Impact factor: 6.244